Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia

• Status: Unknown status
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study period.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abarbanel Mental Health Center
• Treatments: Reboxetine

Criteria

Inclusion Criteria:

• schizophrenia all types

• 18>

Exclusion Criteria:

• uti

• >65

• non organic state

• no depression treatment